{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:43:12Z","timestamp":1784875392285,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K14600"],"award-info":[{"award-number":["23K14600"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K15535"],"award-info":[{"award-number":["21K15535"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37CA248018"],"award-info":[{"award-number":["R37CA248018"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA250412"],"award-info":[{"award-number":["R01CA250412"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA251545"],"award-info":[{"award-number":["R01CA251545"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":[", R01EB029596, W81XWH-19-1-0674 and W81XWH-19-1-0111"],"award-info":[{"award-number":[", R01EB029596, W81XWH-19-1-0674 and W81XWH-19-1-0111"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37CA248018, R01CA250412, R01CA251545, R01EB029596, W81XWH-19-1-0674 and W81XWH-19-1-0111"],"award-info":[{"award-number":["R37CA248018, R01CA250412, R01CA251545, R01EB029596, W81XWH-19-1-0674 and W81XWH-19-1-0111"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37CA248018, R01CA250412, R01CA251545, R01EB029596, W81XWH-19-1-0674 and W81XWH-19-1-0111"],"award-info":[{"award-number":["R37CA248018, R01CA250412, R01CA251545, R01EB029596, W81XWH-19-1-0674 and W81XWH-19-1-0111"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37CA248018, R01CA250412, R01CA251545, R01EB029596, W81XWH-19-1-0674 and W81XWH-19-1-0111"],"award-info":[{"award-number":["R37CA248018, R01CA250412, R01CA251545, R01EB029596, W81XWH-19-1-0674 and W81XWH-19-1-0111"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37CA248018, R01CA250412, R01CA251545, R01EB029596, W81XWH-19-1-0674 and W81XWH-19-1-0111"],"award-info":[{"award-number":["R37CA248018, R01CA250412, R01CA251545, R01EB029596, W81XWH-19-1-0674 and W81XWH-19-1-0111"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02305-9","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:33:34Z","timestamp":1779431614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TP53 mutation is associated with shorter treatment duration with CDK4\/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive\/HER2-negative breast cancer: real-world perspective"],"prefix":"10.1186","volume":"28","author":[{"given":"Masanori","family":"Oshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sugimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipra","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimitsu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Narui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Takabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"26","key":"2305_CR1","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1056\/NEJMra1307118","volume":"383","author":"HJ Burstein","year":"2020","unstructured":"Burstein HJ. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. N Engl J Med. 2020;383(26):2557\u201370.","journal-title":"N Engl J Med"},{"issue":"1","key":"2305_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.trecan.2016.11.006","volume":"3","author":"ES Knudsen","year":"2017","unstructured":"Knudsen ES, Witkiewicz AK. The Strange Case of CDK4\/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. Trends Cancer. 2017;3(1):39\u201355.","journal-title":"Trends Cancer"},{"key":"2305_CR3","doi-asserted-by":"publisher","unstructured":"Lee JS, Hackbart H, Cui X et al. CDK4\/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer: translational research, clinical trials, and future directions. Int J Mol Sci 2023;24(14):11791. https:\/\/doi.org\/10.3390\/ijms241411791","DOI":"10.3390\/ijms241411791"},{"issue":"5","key":"2305_CR4","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/ijc.32020","volume":"145","author":"K Pandey","year":"2019","unstructured":"Pandey K, An HJ, Kim SK, et al. Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: a review. Int J Cancer. 2019;145(5):1179\u201388.","journal-title":"Int J Cancer"},{"issue":"20","key":"2305_CR5","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/jnci\/88.20.1442","volume":"88","author":"CC Harris","year":"1996","unstructured":"Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996;88(20):1442\u201355.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2305_CR6","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s41418-022-00996-z","volume":"29","author":"AF Thomas","year":"2022","unstructured":"Thomas AF, Kelly GL, Strasser A. Of the many cellular responses activated by TP53, which ones are critical for tumour suppression? Cell Death Differ. 2022;29(5):961\u201371.","journal-title":"Cell Death Differ"},{"issue":"1","key":"2305_CR7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","volume":"21","author":"HE Marei","year":"2021","unstructured":"Marei HE, Althani A, Afifi N, et al. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021;21(1):703.","journal-title":"Cancer Cell Int"},{"key":"2305_CR8","first-page":"183","volume":"29","author":"GM Wahl","year":"1997","unstructured":"Wahl GM, Linke SP, Paulson TG, et al. Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv. 1997;29:183\u2013219.","journal-title":"Cancer Surv"},{"issue":"9","key":"2305_CR9","doi-asserted-by":"publisher","first-page":"19257","DOI":"10.3390\/ijms140919257","volume":"14","author":"P Brachova","year":"2013","unstructured":"Brachova P, Thiel KW, Leslie KK. The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci. 2013;14(9):19257\u201375.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2305_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12609-017-0232-0","volume":"9","author":"AC Garrido-Castro","year":"2017","unstructured":"Garrido-Castro AC, Goel S. CDK4\/6 inhibition in breast cancer: mechanisms of response and treatment failure. Curr Breast Cancer Rep. 2017;9(1):26\u201333.","journal-title":"Curr Breast Cancer Rep"},{"issue":"Suppl 1","key":"2305_CR11","doi-asserted-by":"publisher","first-page":"i13","DOI":"10.1093\/jjco\/hyq122","volume":"40","author":"M Toi","year":"2010","unstructured":"Toi M, Ohashi Y, Seow A, et al. The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer. Jpn J Clin Oncol. 2010;40(Suppl 1):i13\u201318.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"2305_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3816\/CBC.2010.n.018","volume":"10","author":"A Naeim","year":"2010","unstructured":"Naeim A, Wong FL, Pal SK, et al. Oncologists\u2019 recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status. Clin Breast Cancer. 2010;10(2):136\u201343.","journal-title":"Clin Breast Cancer"},{"key":"2305_CR13","doi-asserted-by":"publisher","unstructured":"Liu Z, Jiang Z, Gao Y et al. TP53 mutations promote immunogenic activity in breast cancer. J Oncol. 2019;2019:5952836. https:\/\/doi.org\/10.1155\/2019\/5952836","DOI":"10.1155\/2019\/5952836"},{"key":"2305_CR14","doi-asserted-by":"publisher","unstructured":"Wang C, Tan JYM, Chitkara N et al. TP53 mutation-mediated immune evasion in cancer: mechanisms and therapeutic implications. Cancers (Basel) 2024;16(17):3069. https:\/\/doi.org\/10.3390\/cancers16173069","DOI":"10.3390\/cancers16173069"},{"issue":"8","key":"2305_CR15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/bjc.1996.179","volume":"73","author":"A Hartmann","year":"1996","unstructured":"Hartmann A, Blaszyk H, Saitoh S, et al. High frequency of p53 gene mutations in primary breast cancers in Japanese women, a low-incidence population. Br J Cancer. 1996;73(8):896\u2013901.","journal-title":"Br J Cancer"},{"issue":"7403","key":"2305_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346\u201352.","journal-title":"Nature"},{"issue":"5","key":"2305_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"key":"2305_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0056-8","volume":"4","author":"A Mukherjee","year":"2018","unstructured":"Mukherjee A, Russell R, Chin SF, et al. Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort. NPJ Breast Cancer. 2018;4:5.","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"2305_CR19","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","volume":"12","author":"T Kohno","year":"2022","unstructured":"Kohno T, Kato M, Kohsaka S, et al. C-CAT: the national datacenter for cancer genomic medicine in Japan. Cancer Discov. 2022;12(11):2509\u201315.","journal-title":"Cancer Discov"},{"key":"2305_CR20","doi-asserted-by":"publisher","unstructured":"Ebi H, Bando H. Precision oncology and the universal health coverage system in Japan. JCO Precis Oncol 2019; 3:PO.19.00291. https:\/\/doi.org\/10.1200\/PO.19.00291","DOI":"10.1200\/PO.19.00291"},{"issue":"6","key":"2305_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325.","journal-title":"Cell Syst"},{"issue":"23","key":"2305_CR22","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1093\/bioinformatics\/btm369","volume":"23","author":"A Subramanian","year":"2007","unstructured":"Subramanian A, Kuehn H, Gould J, et al. GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics. 2007;23(23):3251\u20133.","journal-title":"Bioinformatics"},{"issue":"8","key":"2305_CR23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","volume":"35","author":"MP Goetz","year":"2024","unstructured":"Goetz MP, Toi M, Huober J, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. 2024;35(8):718\u201327.","journal-title":"Ann Oncol"},{"issue":"2","key":"2305_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-020-05755-7","volume":"183","author":"RS Finn","year":"2020","unstructured":"Finn RS, Boer K, Bondarenko I, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+\/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 2020;183(2):419\u201328.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"2305_CR25","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.00137","volume":"42","author":"DJ Slamon","year":"2024","unstructured":"Slamon DJ, Di\u00e9ras V, Rugo HS, et al. Overall Survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol. 2024;42(9):994\u20131000.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2305_CR26","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.ccell.2024.10.013","volume":"42","author":"R Kudo","year":"2024","unstructured":"Kudo R, Safonov A, Jones C, et al. Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell. 2024;42(11):1983.","journal-title":"Cancer Cell"},{"issue":"11","key":"2305_CR27","doi-asserted-by":"publisher","first-page":"113198","DOI":"10.1016\/j.celrep.2023.113198","volume":"42","author":"S Kim","year":"2023","unstructured":"Kim S, Armand J, Safonov A, et al. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4\/6 inhibitors in breast cancer. Cell Rep. 2023;42(11):113198.","journal-title":"Cell Rep"},{"key":"2305_CR28","doi-asserted-by":"publisher","first-page":"777867","DOI":"10.3389\/fonc.2021.777867","volume":"11","author":"N Portman","year":"2021","unstructured":"Portman N, Chen J, Lim E. MDM2 as a rational target for intervention in CDK4\/6 inhibitor resistant, hormone receptor positive breast cancer. Front Oncol. 2021;11:777867.","journal-title":"Front Oncol"},{"issue":"44","key":"2305_CR29","doi-asserted-by":"publisher","first-page":"e2522646122","DOI":"10.1073\/pnas.2522646122","volume":"122","author":"Y Aylon","year":"2025","unstructured":"Aylon Y, Furth N, Pirona AC, et al. p53 regulates the expression of histone modifiers to restrict stemness and maintain differentiated luminal identity in breast cancer. Proc Natl Acad Sci USA. 2025;122(44):e2522646122.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2305_CR30","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/carcin\/bgt411","volume":"35","author":"KA Avery-Kiejda","year":"2014","unstructured":"Avery-Kiejda KA, Morten B, Wong-Brown MW, et al. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. Carcinogenesis. 2014;35(3):586\u201396.","journal-title":"Carcinogenesis"},{"issue":"4","key":"2305_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4048\/jbc.2023.26.e30","volume":"26","author":"XY Lin","year":"2023","unstructured":"Lin XY, Guo L, Lin X, et al. Concomitant PIK3CA and TP53 mutations in breast cancer: an analysis of clinicopathologic and mutational features, neoadjuvant therapeutic response, and prognosis. J Breast Cancer. 2023;26(4):363\u201377.","journal-title":"J Breast Cancer"},{"key":"2305_CR32","doi-asserted-by":"publisher","unstructured":"Pandey K, Park N, Park KS et al. Combined CDK2 and CDK4\/6 inhibition overcomes palbociclib resistance in breast cancer by enhancing senescence. Cancers (Basel) 2020; 12(12):3566. https:\/\/doi.org\/10.3390\/cancers12123566","DOI":"10.3390\/cancers12123566"},{"issue":"1","key":"2305_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41698-022-00311-6","volume":"6","author":"AJ Al-Qasem","year":"2022","unstructured":"Al-Qasem AJ, Alves CL, Ehmsen S, et al. Co-targeting CDK2 and CDK4\/6 overcomes resistance to aromatase and CDK4\/6 inhibitors in ER+ breast cancer. NPJ Precis Oncol. 2022;6(1):68.","journal-title":"NPJ Precis Oncol"},{"key":"2305_CR34","doi-asserted-by":"publisher","first-page":"104324","DOI":"10.1016\/j.critrevonc.2024.104324","volume":"196","author":"R Gerosa","year":"2024","unstructured":"Gerosa R, De Sanctis R, Jacobs F, et al. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions. Crit Rev Oncol Hematol. 2024;196:104324.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2305_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41523-022-00426-w","volume":"8","author":"Z Li","year":"2022","unstructured":"Li Z, Spoelstra NS, Sikora MJ, et al. Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. NPJ Breast Cancer. 2022;8(1):62.","journal-title":"NPJ Breast Cancer"},{"key":"2305_CR36","doi-asserted-by":"crossref","unstructured":"Tjader NP, Beer AJ, Ramroop J et al. Association of ESR1 germline variants with TP53 somatic variants in breast tumors in a genome-wide study. medRxiv 2023.","DOI":"10.1158\/2767-9764.c.7305359"},{"issue":"6","key":"2305_CR37","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1158\/2767-9764.CRC-24-0026","volume":"4","author":"NP Tjader","year":"2024","unstructured":"Tjader NP, Beer AJ, Ramroop J, et al. Association of ESR1 germline variants with TP53 somatic variants in breast tumors in a genome-wide study. Cancer Res Commun. 2024;4(6):1597\u2013608.","journal-title":"Cancer Res Commun"},{"issue":"11","key":"2305_CR38","doi-asserted-by":"publisher","first-page":"103737","DOI":"10.1016\/j.esmoop.2024.103737","volume":"9","author":"M Oshi","year":"2024","unstructured":"Oshi M, Yamada A, Gandhi S, et al. Breast cancer in adolescents and young adults has a specific biology and poor patient outcome compared with older patients. ESMO Open. 2024;9(11):103737.","journal-title":"ESMO Open"},{"issue":"5","key":"2305_CR39","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.tranon.2018.07.012","volume":"11","author":"Z Jiang","year":"2018","unstructured":"Jiang Z, Liu Z, Li M, et al. Immunogenomics analysis reveals that TP53 mutations inhibit tumor immunity in gastric cancer. Transl Oncol. 2018;11(5):1171\u201387.","journal-title":"Transl Oncol"},{"key":"2305_CR40","doi-asserted-by":"publisher","first-page":"762651","DOI":"10.3389\/fcell.2021.762651","volume":"9","author":"D Shi","year":"2021","unstructured":"Shi D, Jiang P. A different facet of p53 function: regulation of immunity and inflammation during tumor development. Front Cell Dev Biol. 2021;9:762651.","journal-title":"Front Cell Dev Biol"},{"key":"2305_CR41","doi-asserted-by":"publisher","unstructured":"Xiaoguang Li XZ, Yanling Niu T, Ma. Investigating the various predictive values of TP53 mutations for response to immune checkpoint inhibitors (ICIs) in different solid tumors. J Clin Oncol 40: 2022:e14581. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e14581","DOI":"10.1200\/JCO.2022.40.16_suppl.e14581"},{"issue":"7914","key":"2305_CR42","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1038\/s41586-022-04879-8","volume":"606","author":"D Hoyos","year":"2022","unstructured":"Hoyos D, Zappasodi R, Schulze I, et al. Author correction: fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature. 2022;606(7914):E5.","journal-title":"Nature"},{"issue":"10","key":"2305_CR43","doi-asserted-by":"publisher","first-page":"111049","DOI":"10.1016\/j.isci.2024.111049","volume":"27","author":"F Yokoi","year":"2024","unstructured":"Yokoi F, Deguchi S, Watanabe Y, et al. Establishment of an ulcerative colitis model using colon organoids derived from human induced pluripotent stem cells. iScience. 2024;27(10):111049.","journal-title":"iScience"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02305-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02305-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02305-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:12:20Z","timestamp":1784088740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02305-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2305"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02305-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8082446\/v1","asserted-by":"object"}]},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The METABRIC dataset is publicly available and therefore exempt from ethical approval. The use of C-CAT data in this study was reviewed and approved by the Ethical Advisory Committee of YCU (IRB approval number: F250900014). All data analyzed were fully de-identified in accordance with applicable ethical guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this study used de-identified secondary data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"130"}}